The potential of bioartificial tissues in oncology research and treatment

Onkologie

Volumn 30, Issue 7, 2007, Pages 388-394

  Walles, T ^a   Weimer, M ^b   Linke, K ^b   Michaelis, J ^b   Mertsching, H ^b  

^a Klinik Schillerhohe   (Germany)

^b FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB   (Germany)

Author keywords

Drug development; Reconstructive surgery; Test systems; Tissue differentiation; Tissue engineering

Indexed keywords

ANGIOGENESIS; BIOARTIFICIAL ORGAN; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CELL CULTURE; EXPERIMENTAL STUDY; HUMAN; IMPLANT; IN VITRO STUDY; INTERVENTION STUDY; MICROENVIRONMENT; MOLECULAR MIMICRY; MOLECULAR MODEL; NONHUMAN; ONCOLOGY; PLASTIC SURGERY; REVIEW; TISSUE CULTURE; TISSUE DIFFERENTIATION; TISSUE ENGINEERING;

ANTINEOPLASTIC AGENTS; BIOARTIFICIAL ORGANS; BIOMEDICAL RESEARCH; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MELANOMA, EXPERIMENTAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEOMICS; TISSUE ENGINEERING; TUMOR STEM CELL ASSAY;

EID: 34347339477     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102544     Document Type: Review

References (60)

1. Koshy M, Esiavilli N, Landry JC, Thomas CR, Matthews RH: Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist 2004;9:147-59.
2. van Meerten E, van der Gaast A: Systemic treatment for oesophageal cancer. Eur J Cancer 2005;41:664-72.
3. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R: The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004;9:273-85.
4. http://merck.de
5. Fuchs JR, Nasseri BA, Vacanti JP: Tissue engineering: a 21st century solution to surgical reconstruction. Ann Thorac Surg 2001;72:577-91.
6. Atala A: Tissue engineering and regenerative medicine: concepts for clinical application. Rejuvenation Res 2004;7:15-31.
7. Gomes ME, Reis RL: Tissue engineering: key elements and some trends. Macromol Biosci 2004;4:737-42.
8. Wakatsuki T, Elson EL: Phenotypic screening for pharmaceuticals using tissue constructs. Curr Pharm Biotechnol 2004;4:181-9.
9. Langer R, Vacanti JP: Tissue engineering. Science 1993;260:920-6.
10. Vacanti JP, Langer R: Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet 1999;354(suppl):S132-4.
11. Schmidt A, Ladage D, Schinkothe T, Klausmann U, Ulrichs C, Klinz FJ, Brixius K, Arnold S, Desai B, Mehlhorn U, Schwinger H, Staib P, Addicks K, Bloch W: Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells 2006;24:1750-8.
12. Son BR, Marquez-Curtis LA, Kucia M, Wysoczynski M, Turner AR, Ratajczak J, Ratajzak MZ, Janowska-Wieczorek A: Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006;24:1254-64.
13. Smits AM, van Vliet P, Hassink RJ, Goumans MJ, Doevendans PA: The role of stem cells in cardiac regeneration. J Cell Mol Med 2005;9:25-36.
14. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespade DA, Verfaillie CM: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9.
15. Song L, Young NJ, Webb NE, Tuan RS: Origin and characterization of multipotential mesenchymal stem cells derived from adult human trabecular bone. Stem Cells Dev 2005;14:712-21.
16. Dietrich C, Schandar M, Noll M, Johannes FJ, Brunner H, Graeve T, Rupp S: In vitro reconstructed human epithelia reveal contribution of Candida albicans EFG1 and CPH1 to adhesion and invasion. Microbiology 2002;148:497-506.
17. Lindahl A, Brittberg M, Peterson L: Cartilage repair with chondrocytes: clinical and cellular aspects. Novartis Found Symp 2003;249:175-86.
18. Gulbins H, Goldemund A, Uhlig A, Pritisanac A, Meiser B, Reihart B: Implantation of an autologously endothelialized homograft. J Thorac Cardiovasc Surg 2003;126:890-1.
19. Hoerstrup SP, Zund G, Schnell AM, Kolb SA, Visjager JF, Schoeberlein A, Turina M: Optimized growth conditions for tissue engineering of human cardiovascular structures. Int J Artif Organs 2000;23:817-23.
20. Schultheiss D, Gabouev AI, Cebotari S, Tudorache I, Walles T, Schlote N, Wefer J, Kaufmann PM, Haverich A, Jonas U, Stief CG, Mertsching H: Biological vascularized matrix for bladder tissue engineering: matrix preparation, reseeding technique and short-term implantation in a porcine model. J Urol 2005;173:276-80.
21. Atala A: Regeneration of urologic tissues and organs. Adv Biochem Eng Biotechnol 2005;94:181-210.
22. Mistry AS, Mikos AG: Tissue engineering strategies for bone regeneration. Adv Biochem Eng Biotechnol 2005;94:1-22.
23. Stocum DL: Stem cells in CNS and cardiac regeneration. Adv Biochem Eng Biotechnol 2005;94:135-59.
24. Walles T, Biancosino C, Zardo P, Macchiarini P, Gottlieb J, Mertsching H: Tissue remodeling in a bioartificial fibromuscular patch following transplantation in human. Transplant 2005;80:284-5.
25. Walles T, Herden T, Haverich A, Mertsching H: Influence of scaffold thickness and scaffold composition on bioartificial graft survival. Biomaterials 2003;24:1233-9.
26. Klepetko W, Marta GM, Wisser W, Melis E, Kocher A, Seebacher G, Aigner C, Mazhar S: Heterotopic tracheal transplantation with omentum wrapping in the abdominal position preserves functional and structural integrity of a human tracheal allograft. J Thorac Cardiovasc Surg 2004;127:862-7.
27. Mertsching H, Walles T, Hofmann M, Schanz J, Knapp WH: Engineering of a vascularized scaffold for artificial tissue and organ generation. Biomaterials 2005;26:6610-7.
28. Schmeichel KL, Bissell MJ: Modeling tissue-specific signaling and organ function in three dimensions. J Cell Sci 2003;116:2377-88.
29. Sundberg SA: High-throughput and ultra-highthroughput screening: solution and cell based approaches. Curr Opin Biotechnol 2000;11:47-53.
30. Balis FM: Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst 2002;94:78-9.
31. Guillouzo A: Liver cell models in in vitro toxicology. Environ Health Perspect 1998;106(suppl 2):511-32.
32. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD: Molecular Biology of the Cell, ed 3. New York, Garland Publishing, 1994.
33. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell JE: Molecular Cell Biology, ed 4. New York, W. H. Freeman & Co, 2000.
34. Darnell JE: Special Achievement in Medical Science Award. The surprises of mammalian molecular cell biology. Nat Med 2002;8:1068-71.
35. Voigt W, Pickan V, Pfeiffer C, Mueller T, Simon H, Arnold D: Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines - implications for clinical use. Onkologie 2005;28:482-8.
36. Kleine W: Transplantation of malignant ovarian tumors into athymic nu/nu mice. Onkologie 1984;7(suppl 2):74-80.
37. Martins-Green M: Dynamics of cell-ECM interactions; in Lanza RP, Langer R, Vacanti JP (eds): Principles of Tissue Engineering, ed 2. New York, Academic Press, 2002.
38. Abbott A: Cell culture: biology's new dimension. Nature 2003;424:870-2.
39. Zahir N, Weaver VM: Death in the third dimension: apoptosis regulation and tissue architecture. Curr Opin Genet Dev 2004;14:71-80.
40. Inch WR, McCredie JA, Sutherland RM: Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture. Growth 1970;34:271-82.
41. Sutherland RM, McCredie JA, Inch WR: Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst 1971;46:113-120.
42. Kunz-Schughart LA, Kreutz M, Knuechel R: Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol 1998;79:1-23.
43. Mueller-Klieser W: Three-dimensional cell cultures: from molecular mechanisms to clinical applications. Am J Physiol 1997;273:C1109-23.
44. Bhadriraju K, Chen CS: Engineering cellular microenvironment to improve cell-based drug testing. Drug Discov Today 2002;7:612-20.
45. Powell DW, Adegboyega PA, Di Mari JF, Mifflin RC: Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am J Physiol Gastrointest Liver Physiol 2005;289:G2-7.
46. Mueller-Klieser W: Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol 2000;36:123-39.
47. Ame-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S, Guillaudeux T, Lamy T, Fest T, Tarte K: Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 2007;109:693-702.
48. Desmouliere A, Guyot C, Gabbiani G: The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 2004;48:509-17.
49. Oudar O: Spheroids: relation between tumour and endothelial cells. Crit Rev Oncol Hematol 2000;36:99-106.
50. Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München, Germany: Dreidimensionales Hautmodell. EP 01953961.8-2405.
51. Kersen S: Zelluläre Erweiterung des dreidimensionalen humanen Hautäquivalents mit mikrovaskulären Endothelzellen (HDMEC) mit dem Ziel ein in vitro Angiogenese-Modell zu etablieren. Diplomarbeit 2004, Hochschule Niederrhein und Fraunhofer IGB.
52. Biancosino C, Zardo P, Walles T, Wildfang I, Macchiarini P, Mertsching H: Generation of a bioartificial fibromuscular tissue with autoregenerative capacities for tracheal reconstruction. Cytotherapy 2006;8:178-83.
53. Levenberg S, Langer R: Advances in tissue engineering. Curr Top Dev Biol 2004;61:113-28.
54. Jain RK: Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.
55. Polverini PJ: Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. J Dent Educ 2002;66:962-75.
56. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditi JM, Schepartz S: Relationship between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31.
57. Abuin A, Holt KH, Platt KA, Sands AT, Zambrowicz BP: Full-speed mammalian genetics: in vivo target validation in the drug discovery process.Trends Biotechnol 2002;20:36-42.
58. Thyagarajan T, Totey S, Danton MJ, Kulkarni AB: Genetically altered mouse models: the good, the bad, and the ugly. Crit Rev Oral Biol Med 2003;14:154-74.
59. Gori GB: Are animal tests relevant in cancer risk assessment? A persistent issue becomes uncomfortable. Regul Toxicol Pharmacol 1992;13:225-7.
60. Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat MM, Untch M, Konecny G, Bruckner HW, Cree IA: ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results Cancer Res 2003;161:221-30.